Regenxbio宣布与FDA就Navsunli™加速批准BLA重新提交路径达成一致;首款潜在MPS II基因疗法

美股速递
Jun 22

Regenxbio公司近日宣布,已与美国食品药品监督管理局就Navsunli™生物制品许可申请的重新提交路径达成一致,旨在寻求加速批准。该疗法有望成为针对黏多糖贮积症II型的首款基因疗法。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10